Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRINCE: Pegcetacoplan in Naïve PNH Patients
NCT04085601Phase 3Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Jun 2021
- Modality
- PEGylated Peptides
- Countries
- 10
01
Overview
A Phase 3 trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Apellis Pharmaceuticals. Started Aug 2019; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04085601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04085601.